Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart F… (NCT01920048) | Clinical Trial Compass
CompletedNot Applicable
Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure
United Kingdom700 participantsStarted 2013-08-28
Plain-language summary
This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Poor left ventricular function (EF≤35%)
. Extensive coronary disease
. Viability in at least 4 dysfunctional segments that can be revascularised by PCI
. Decompensated heart failure requiring inotropic support, invasive or non-invasive ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy \<72 hours prior to randomization
. Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable Cardioverter Defibrillator discharges \<72 hours prior to randomization
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial studied whether opening blocked heart arteries with a procedure called PCI actually reduces the risk of death or hospitalization for heart failure in people with ischemic cardiomyopathy — what did the results show, and do they change how you'd approach my treatment?
2Since this trial is now completed, has the data been published, and does it suggest that PCI provided a meaningful survival benefit compared to managing ischemic cardiomyopathy with medications alone?
3The trial tracked both all-cause death and heart failure hospitalizations as its main outcomes — based on those results, how does my specific situation compare to the types of patients who were enrolled, and would I likely have similar risks?
4Given that this was a completed trial rather than an ongoing one, are there now updated guidelines or new evidence it helped produce that should shape the decisions we make about my care?
5Would you recommend PCI for my ischemic cardiomyopathy based on what this trial found, or is there a reason you might suggest a different approach like medication management or another procedure first?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
All-cause death or Hospitalization for Heart Failure
Timeframe: 1 to 103 months (min follow-up duration: 24 months)